Innoviva Aktie News

Weltweite Biosicherheitswarnungen schlagen an, nachdem ein Vorfall in einer Anti-Pest-Forschungseinrichtung in Sibirien eine schwere Gesundheitsreaktion ausgelöst hat. Nach der tödlichen Laborexposition eines Forschers in der Region Irkutsk gegenüber Yersinia pestis – dem Bakterium, das die Lungenpest verursacht – stellten russische Behörden mehrere regionale Krankenhäuser unter Quarantäne und ...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), eine Tochtergesellschaft von Innoviva, Inc. (NASDAQ: INVA), gab heute bekannt, dass drei der Infektionstherapien des Unternehmens, XACDURO® (sulbactam/durlobactam zur Injektion), ZEVTERA® (ceftobiprole medocaril sodium zur Injektion) und NUZOLVENCE® (zoliflodacin), als Finalisten für den Prix Galien USA 2026 in der Kategori...

LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. T...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the f...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter en...

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.